[go: up one dir, main page]

WO1992001675A3 - Composes bis-aryle bicycliques substitues ayant une activite antagoniste selective sur le leukotriene b4, leur preparation et utilisation dans des compositions pharmaceutiques - Google Patents

Composes bis-aryle bicycliques substitues ayant une activite antagoniste selective sur le leukotriene b4, leur preparation et utilisation dans des compositions pharmaceutiques Download PDF

Info

Publication number
WO1992001675A3
WO1992001675A3 PCT/EP1991/001341 EP9101341W WO9201675A3 WO 1992001675 A3 WO1992001675 A3 WO 1992001675A3 EP 9101341 W EP9101341 W EP 9101341W WO 9201675 A3 WO9201675 A3 WO 9201675A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutical compositions
antagonist activity
substituted bicyclic
compounds exhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1991/001341
Other languages
English (en)
Other versions
WO1992001675A2 (fr
Inventor
Norbert Dereu
Wolfram Hendel
Richard Labaudiniere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to FI930256A priority Critical patent/FI930256A0/fi
Priority to JP91512181A priority patent/JPH05508845A/ja
Priority to US07/966,151 priority patent/US5366982A/en
Publication of WO1992001675A2 publication Critical patent/WO1992001675A2/fr
Publication of WO1992001675A3 publication Critical patent/WO1992001675A3/fr
Priority to CS924031A priority patent/CZ403192A3/cs
Priority to NO93930201A priority patent/NO930201L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés ayant des propriétés antagonistes sélectives sur LTB4 et comprenant un anneau aryle ou hétéroaryle monocyclique ou bicyclique qui possède au moins deux substituants rattachés: (1) un anneau aryle ou hétéroaryle monocyclique ou bicylique substitué ou non substitué et (2) une chaîne de substitution ayant un groupe fonctionnel acide carboxylique terminal ou un dérivé de celui-ci rattaché à la chaîne. Cette invention concerne en outre des procédés pour la préparation de ces composés ainsi que des compositions thérapeutiques comprenant ledit composé, et des procédés pour le traitement de troubles impliquant une activité induite par un antagoniste LTB4 en utilisant lesdites compositions dans lesquelles les composés sont décrits par la formule générale (I) et leurs sels pharmaceutiquement acceptables.
PCT/EP1991/001341 1990-07-24 1991-07-18 Composes bis-aryle bicycliques substitues ayant une activite antagoniste selective sur le leukotriene b4, leur preparation et utilisation dans des compositions pharmaceutiques Ceased WO1992001675A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FI930256A FI930256A0 (fi) 1990-07-24 1991-07-18 Substituerade bicykliska bis-arylfoereningar med selektiv antagonistiskaktivitet mot leukotrien b4, framstaellning och anvaendning daerav i farmaceutiska kompositioner
JP91512181A JPH05508845A (ja) 1990-07-24 1991-07-18 選択的ロイコトリエンｂ４拮抗活性を示す置換２環式ビス―アリール組成物、それらの調製および医薬組成物における使用
US07/966,151 US5366982A (en) 1990-07-24 1991-07-18 Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene B4 antagonist activity, their preparation and use in pharmaceutical compositions
CS924031A CZ403192A3 (en) 1990-07-24 1992-12-31 Substituted bicyclic bis-aryl derivatives, process of their preparation and their use in pharmaceutical compositions
NO93930201A NO930201L (no) 1990-07-24 1993-01-21 Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9009453A FR2665159B1 (fr) 1990-07-24 1990-07-24 Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR90/09453 1990-07-24

Publications (2)

Publication Number Publication Date
WO1992001675A2 WO1992001675A2 (fr) 1992-02-06
WO1992001675A3 true WO1992001675A3 (fr) 1992-08-06

Family

ID=9399053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/001341 Ceased WO1992001675A2 (fr) 1990-07-24 1991-07-18 Composes bis-aryle bicycliques substitues ayant une activite antagoniste selective sur le leukotriene b4, leur preparation et utilisation dans des compositions pharmaceutiques

Country Status (15)

Country Link
US (2) US5366982A (fr)
EP (1) EP0540604A1 (fr)
JP (1) JPH05508845A (fr)
AU (1) AU8194891A (fr)
CA (1) CA2087848A1 (fr)
CZ (1) CZ403192A3 (fr)
FI (1) FI930256A0 (fr)
FR (1) FR2665159B1 (fr)
HU (1) HUT68663A (fr)
IE (1) IE912589A1 (fr)
IL (1) IL98921A0 (fr)
NO (1) NO930201L (fr)
PT (1) PT98438A (fr)
WO (1) WO1992001675A2 (fr)
ZA (1) ZA915759B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
FR2705959B1 (fr) * 1993-06-01 1995-08-11 Oreal Procédé de synthèse stéréospécifique de leucotriène B4 sous sa configuration 6Z, 8E, 10E et produits intermédiaires.
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
JP2866202B2 (ja) * 1994-04-13 1999-03-08 エフ・ホフマン−ラ ロシュ アーゲー 置換ピリジンロイコトリエンｂ▲下４▼拮抗物質
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
US5556990A (en) * 1994-12-16 1996-09-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
US6103465A (en) * 1995-02-14 2000-08-15 The Perkin-Elmer Corporation Methods and reagents for typing HLA class I genes
US5571825A (en) * 1995-03-31 1996-11-05 Warner-Lambert Company Method of selectively inhibiting prostaglandin G/H synthase-2
AU6269496A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotrien e b4 receptor antagonist for the treatment of infla mmations
EP1640003A2 (fr) 1996-02-13 2006-03-29 G.D. SEARLE & CO. Compositions renfermant un inhibiteur de cyclooxygenase-2 et un antagoniste de recepteur de leucotriene b4
AU736481C (en) * 1996-10-07 2002-06-06 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation
US20030124053A1 (en) * 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
US6416733B1 (en) * 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
AU6572298A (en) * 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
CA2360740A1 (fr) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
CA2383999A1 (fr) * 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Nouvelle classe d'agents de cytodifferentiation et inhibiteurs de desacetylase de l'histone, et leurs procedes d'utilisation
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6812237B2 (en) 2000-05-15 2004-11-02 Novartis Ag N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
US20020198207A1 (en) * 2000-05-18 2002-12-26 Kath John Charles Novel Hexanoic acid derivatives
US6696466B1 (en) 2000-09-07 2004-02-24 Leslie Joe Dunaway Methods of treating select neuronal inflammatory disorders using hydroxyalkylquinolines
WO2002083143A1 (fr) 2000-12-11 2002-10-24 Tularik Inc. Antagonistes de cxcr3
JP2004525139A (ja) * 2001-03-23 2004-08-19 中外製薬株式会社 Ｆｌｔ−１リガンド、および血管形成により調節可能な疾患の治療におけるそれらの使用
TWI316055B (fr) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
DE60305446D1 (de) 2002-01-07 2006-06-29 Eisai Co Ltd Desazapurine und deren verwendung
WO2003070701A2 (fr) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses de quinazolinones
US6921752B2 (en) * 2002-03-26 2005-07-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of LTB4 antagonists in veterinary medicine
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
BR0309892A2 (pt) * 2002-05-09 2011-04-05 Cytokinetics Inc composto, composição, métodos para modular a atividade da cinesina de ksp, para inibir a ksp, e para o tratamento de uma doença proliferativa celular, e, uso de um composto
AU2003270015A1 (en) * 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
US7038048B2 (en) * 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
US7041676B2 (en) * 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (fr) * 2002-07-23 2008-04-16 Cytokinetics Inc Composes, compositions et procedes
EP1539180A4 (fr) * 2002-08-21 2006-08-30 Cytokinetics Inc Composes, compositions et methodes
WO2004029204A2 (fr) * 2002-09-27 2004-04-08 Merck & Co., Inc. Pyrimidines substituees
JP2006501306A (ja) * 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
BR0317313A (pt) 2002-12-16 2005-11-08 Astrazeneca Uk Ltd Processo para a preparação de um composto, e, composto
CN1839121A (zh) * 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
WO2004094379A2 (fr) * 2003-04-16 2004-11-04 Amgen Inc. Composes heterocycliques substitues et leurs procedes d'utilisation
RU2356896C2 (ru) 2003-04-16 2009-05-27 Ф.Хоффманн-Ля Рош Аг Производные хиназолина
DK2520654T3 (en) 2003-08-26 2017-05-01 Univ Colorado Regents Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−４−オン化合物、組成物、および方法
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
JP2007513154A (ja) * 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
WO2005097137A2 (fr) * 2004-03-31 2005-10-20 The Scripps Research Institute Inhibiteurs de proteines kinases ameliores a base de quinazoline
KR20070026503A (ko) * 2004-05-14 2007-03-08 아이알엠 엘엘씨 Ｐｐａｒ 조절제로서의 화합물 및 조성물
WO2005115148A1 (fr) * 2004-05-24 2005-12-08 Cropsolution, Inc. Esters d'acide 3-aryl-3-hydroxy-2-methylenepropionique utilises en tant que fongicides
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
DE102005044156A1 (de) * 2005-09-15 2007-03-29 Riemser Arzneimittel Ag Substituierte Acetophenonderivate
SI1963280T1 (sl) 2005-12-22 2016-02-29 Newron Pharmaceuticals S.P.A. 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0716815A2 (pt) * 2006-09-07 2013-11-05 Allergan Inc Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p)
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
EP2133095A4 (fr) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd Composition pharmaceutique
US8093253B2 (en) 2008-03-06 2012-01-10 Hoffmann-La Roche Inc. Leukotriene B4 inhibitors
JP5394487B2 (ja) 2008-07-15 2014-01-22 エフ．ホフマン−ラ ロシュ アーゲー アミノテトラヒドロインダゾロ酢酸
CA2730390A1 (fr) 2008-07-15 2010-01-21 F.Hoffmann-La Roche Ag Acides aminotetrahydroindazoloacetiques
JP5302398B2 (ja) 2008-08-15 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー 置換アミノテトラリン
WO2010018113A2 (fr) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryle aminotétralines
JP2012508715A (ja) 2008-11-17 2012-04-12 エフ．ホフマン−ラ ロシュ アーゲー ナフチル酢酸
JP5373104B2 (ja) 2008-11-17 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｔｈ２アンタゴニスト又は部分アゴニストとして使用されるナフチル酢酸
SG171734A1 (en) 2008-11-17 2011-07-28 Hoffmann La Roche Naphthylacetic acids
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010144647A1 (fr) 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Composés de nicotinamide utiles en tant que modulateurs de kinases
CN103052628B (zh) 2010-07-20 2016-05-18 韦斯塔隆公司 三嗪类和嘧啶类杀虫剂
WO2012060847A1 (fr) 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procédés de traitement de la myélofibrose
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
CA2848631C (fr) 2011-09-16 2019-10-01 Hetero Research Foundation Chlorhydrate de rilpivirine
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
MX378007B (es) * 2013-06-27 2025-03-10 Lg Chemical Ltd Derivados de biarilo como agonistas de gpr120.
CA2959208C (fr) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Derives de pyrimidine et utilisation comme inhibiteurs de .alpha.-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
EP3239143B1 (fr) * 2014-12-24 2023-03-22 LG Chem, Ltd. Dérivé de biaryle utilisable en tant qu'agoniste du gpr120
EP3939973A1 (fr) 2015-07-06 2022-01-19 Alkermes, Inc. Inhibiteurs hétéro-halo d'histone désacétylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
EP3350146A4 (fr) * 2015-09-14 2019-03-06 The Regents of The University of California Préparation d'acides gras de furane à partir de 5-(chlorométhyl)furfural
DK3570834T3 (en) 2017-01-11 2022-02-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
SMT202200232T1 (it) 2017-08-07 2022-07-21 Alkermes Inc Inibitori biciclici di istone deacetilasi
US11731946B2 (en) 2017-10-19 2023-08-22 The General Hospital Corporation Broad spectrum antivirulence, anti-persistence compounds
US20230210837A1 (en) * 2021-12-31 2023-07-06 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds
CN116874433A (zh) * 2023-06-16 2023-10-13 上海应用技术大学 一种嘧啶类化合物及其合成方法及应用
CN118745145A (zh) * 2024-06-24 2024-10-08 湖南大学 一类2-羟基吡啶类衍生物及其合成方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5035M (fr) * 1964-07-28 1967-05-02
EP0090353A1 (fr) * 1982-03-27 1983-10-05 Hoechst Aktiengesellschaft Dérivés de la 2-pyridone, leur méthode de préparation et les médicaments les contenant
EP0210084A1 (fr) * 1985-05-30 1987-01-28 Rhone-Poulenc Sante Amides, procédés pour leur préparation et médicaments les contenant
WO1987005510A1 (fr) * 1986-03-13 1987-09-24 Rorer International (Overseas) Inc. Tetrazoles de thioether ou d'ether de quinolinyle utilises comme agents pour le traitement de troubles d'hypersensibilite
EP0318083A2 (fr) * 1987-11-25 1989-05-31 Merck Frosst Canada Inc. Acides pyridyl-dialkanoides et leur utilisation comme médicaments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5758666A (en) * 1980-09-24 1982-04-08 Otsuka Pharmaceut Co Ltd Alkanoic acid derivative
CA1315279C (fr) * 1987-01-12 1993-03-30 Nancy Grace Bollinger Agents antiinflammatoires
CA1320490C (fr) * 1987-01-12 1993-07-20 Darrel M. Gapinski Agents antiinflammatoires
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
WO1989011279A1 (fr) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Compose heteropolycyclique non fusionne ayant une interaction avec des acides nucleiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5035M (fr) * 1964-07-28 1967-05-02
EP0090353A1 (fr) * 1982-03-27 1983-10-05 Hoechst Aktiengesellschaft Dérivés de la 2-pyridone, leur méthode de préparation et les médicaments les contenant
EP0210084A1 (fr) * 1985-05-30 1987-01-28 Rhone-Poulenc Sante Amides, procédés pour leur préparation et médicaments les contenant
WO1987005510A1 (fr) * 1986-03-13 1987-09-24 Rorer International (Overseas) Inc. Tetrazoles de thioether ou d'ether de quinolinyle utilises comme agents pour le traitement de troubles d'hypersensibilite
EP0318083A2 (fr) * 1987-11-25 1989-05-31 Merck Frosst Canada Inc. Acides pyridyl-dialkanoides et leur utilisation comme médicaments

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, volume 97, 1982 (Columbus, Ohio, US) see page 617, abstract 110032x, & JP, A, 8258666 (OTSUKA PHARMACEUTICAL CO., LTD) 8 April 1982 (cited in the application) *
J. Med. Chemistry, volume 33, no. 4, 1990, American Chemical Society, R.D. Youssefyeh et al.: "Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships", pages 772-777, see table I, compound 17 *
J. Med. chemistry, volume 34, no. 2, 1991, American Chemical Society, C.R. Self et al.: ""Romazarit: a potential disease-modifying antirheumatic drug", pages 772-777, see table I, compound 17 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases

Also Published As

Publication number Publication date
FI930256L (fi) 1993-01-22
FI930256A7 (fi) 1993-01-22
US5366982A (en) 1994-11-22
NO930201D0 (no) 1993-01-21
ZA915759B (en) 1992-05-27
IL98921A0 (en) 1992-07-15
EP0540604A1 (fr) 1993-05-12
US5492915A (en) 1996-02-20
FR2665159B1 (fr) 1992-11-13
CA2087848A1 (fr) 1992-01-25
HU9300190D0 (en) 1993-04-28
NO930201L (no) 1993-01-21
HUT68663A (en) 1995-07-28
JPH05508845A (ja) 1993-12-09
FR2665159A1 (fr) 1992-01-31
IE912589A1 (en) 1992-01-29
FI930256A0 (fi) 1993-01-22
PT98438A (pt) 1992-05-29
AU8194891A (en) 1992-02-18
WO1992001675A2 (fr) 1992-02-06
CZ403192A3 (en) 1993-09-15

Similar Documents

Publication Publication Date Title
WO1992001675A3 (fr) Composes bis-aryle bicycliques substitues ayant une activite antagoniste selective sur le leukotriene b4, leur preparation et utilisation dans des compositions pharmaceutiques
CA2005986A1 (fr) Derive de benzimidazole ayant un effet inhibiteur sur l'acide gastrique et procede de preparation correspondant
NO900306D0 (no) Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
RU93058555A (ru) Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения или профилактики
AU5681800A (en) Quinoline derivatives as antibacterials
TW369535B (en) A pyrazolopyridine compound and the process for preparing thereof
RU94019971A (ru) Производные 1,3-дигидро-2н-имидазо /4,5-в/хинолин-2-она в качестве ингибиторов, фосфодиэстеразы, способ их получения, промежуточные для них, фармацевтическая композиция и способ ее получения
RU93004793A (ru) Производные хиназолина, способ их получения, фармацевтическая композиция на их основе
CA2122236A1 (fr) Composes heterocycliques
DE69528005D1 (de) Prolineamid-Derivate
WO2001072728A3 (fr) Nouveaux derives de piperazine
CA2190973A1 (fr) Nouveaux derives 4,6-diarylpyrimidine et leurs sels
NZ318874A (en) Indoline and quinoline derivatives, preparation and pharmaceutical compositions thereof
CA2356380A1 (fr) Effets immunosuppresseurs de derives de la pteridine
IE45256L (en) Quinazolone derivatives
DE19652239A1 (de) Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
CA2233315A1 (fr) Compositions pharmaceutiques contenant des derives d'acide hydroximique
ATE146473T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung
HK1046405A1 (zh) 作为nmda受体拮抗剂用於治疗疼痛的取代的1，5-二氢吡咯-2-酮衍生物
CA2124455A1 (fr) Derives indole, methode de production et utilisation en medecine
WO2002102787A3 (fr) Nouveaux derives d'acide sulfonique
CA2114727A1 (fr) Derives quinoline utilises comme immunostimulants
EP0538416A4 (en) Substituted monocyclic aryl compounds exhibiting selective leukotriene b 4? antagonist activity
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
AU1719392A (en) Leukotriene b4 antagonist

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CS FI HU JP KR NO SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CS FI HU JP KR NO SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: PV1992-4031

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1991913522

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2087848

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 930256

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1991913522

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1992-4031

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1992-4031

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1991913522

Country of ref document: EP